Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children's Oncology Group.
暂无分享,去创建一个
L. Mirabello | D. Malkin | N. Pankratz | A. Sarver | A. J. Hooten | L. Spector | L. Mills | B. Diessner | Ava C Kelley | Brandon J Diessner